A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma

This clinical research study looked at a new combination of chemotherapy drugs (Idarubicin and Methotrexate) followed by a lower dose of radiotherapy in participants with Primary Central Nervous System Lymphoma (PCNSL). The main purpose of this study was to assess the effectiveness of this treatment and its effect on the ability of patients to perform normal daily functions. In addition the acute effects of the chemotherapy was assessed.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

ALLG, Amgen (Neupogen)

Final Accrual

20

Trial Chairperson

Dr Peter O’Brien, Calvary Mater Newcastle, NSW

Clinical Trial Registration

Related Post

26 November, 2025

TROG Member Prof Paul Keall’s innovative research recognised in two Premier’s Awards

LATEST NEWS; 26 November 2025 Medical physics researcher and

25 November, 2025

Automated quality assurance tool shows promise in TROG 18.01 NINJA trial

LATEST NEWS: 25 November 2025 Vital quality assurance (QA)